Jump to content

Examine individual changes

This page allows you to examine the variables generated by the Edit Filter for an individual change.

Variables generated for this change

VariableValue
Edit count of the user (user_editcount)
null
Name of the user account (user_name)
'86.146.229.123'
Age of the user account (user_age)
0
Groups (including implicit) the user is in (user_groups)
[ 0 => '*' ]
Whether or not a user is editing through the mobile interface (user_mobile)
false
Page ID (page_id)
1430307
Page namespace (page_namespace)
0
Page title without namespace (page_title)
'Nicotine patch'
Full page title (page_prefixedtitle)
'Nicotine patch'
Last ten users to contribute to the page (page_recent_contributors)
[ 0 => 'Flyer22', 1 => 'Frank Becher', 2 => 'ClueBot NG', 3 => '192.0.157.131', 4 => 'Juhuyuta', 5 => '58.178.62.72', 6 => 'Kilroywasnthere', 7 => 'BattyBot', 8 => 'Alexis1812w', 9 => '99.105.22.199' ]
Action (action)
'edit'
Edit summary/reason (summary)
''
Whether or not the edit is marked as minor (no longer in use) (minor_edit)
false
Old page wikitext, before the edit (old_wikitext)
'{{Cleanup|date=July 2009}} [[Image:Nicoderm.JPG||thumb|right|A 21 mg dose [[Nicoderm]] CQ patch applied to the left arm]] A '''nicotine patch''' is a [[transdermal patch]] that releases [[nicotine]] into the body through the skin. It is used as an aid in [[nicotine replacement therapy]] (NRT), a process for [[smoking cessation]]. The first study of the pharmacokinetics of a transdermal nicotine patch in humans was published in 1984<ref>{{cite pmid | 6734425 }}</ref> by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, and was followed by publication by Rose et al. (1985) of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes.<ref>{{cite pmid | 4042528 }}</ref> Frank Etscorn filed a patent in the [[United States]] on January the 23rd 1985 and was issued the patent on July 1, 1986.<ref>{{ cite patent | country = US | number = 4597961 | status = | title = | pubdate = | gdate = | fdate = | pridate = | inventor =Etscorn, FT | invent1 = | invent2 = | assign1 = | assign2 = | class = }}</ref> The University of California filed a competing patent application nearly 3 years after Etscorn's filing on February the 19th, 1988, which was granted on May 1, 1990.<ref>{{cite patent | country = US | number = 4920989 }}</ref> Subsequently, the U.S. Patent Office declared an interference action and, after a thorough review of conception, reduction to practice and patent filing dates, issued on September 29, 1993 a priority decision in favor of the Rose et al. patent.<ref>{{cite web|title=Adverse Decisions in Interference|url=http://www.uspto.gov/web/offices/com/sol/og/1995/week08/patadve.htm|accessdate=25 November 2013|date=21 February 1995|publisher= Board of Patent Appeals & Interferences|author=OLIVIA M. DUVALL}}</ref> Eventually New Mexico Tech and Etscorn won discovery. ==Issues== ===Efficacy=== Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment. Placebo tests show a 5.9% success rate, in comparison to the 7.2% blind active tests, and the 10.8% open tests.<ref>{{cite web|last=Renshaw|first=Amy|title=The Real Story Behind the Nicotine Patch and Smoking Cessation|url=http://healthpsych.psy.vanderbilt.edu/health-patch.htm|work=vanderbilt.edu|publisher=Vanderbilt University|accessdate=25 November 2013}}</ref><ref>Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009</ref> ===Toxicity=== Analysis of nicotine patches has shown that they contain [[tobacco-specific nitrosamines]] (TSNAs), known cancer-causing agents, in quantities of up to 173&nbsp;ng per patch.<ref>UCSF Library, 3 Feb 1995, [http://www.legacy.library.ucsf.edu/documentStore/n/y/a/nya24e00/Snya24e00.pdf Tobacco-Specific N-Nitrosamines in Nicotine Patches], retrieved 11 Aug 2013.</ref> ==Alternate uses== Nicotine patches are under study to help relieve the symptoms of [[post-surgical pain]] <ref>{{cite web|title=Nicotine Patch Decreases Post Surgical Pain|url=http://www.medicalnewstoday.com/releases/85508.php|publisher=MediLexicon International Ltd, Bexhill-on-Sea, UK|accessdate=25 November 2013|date=15 October 2007}}</ref> and treat early [[dementia]]. <ref>{{cite web|title=Nicotine Patches Up Early Memory Loss In Study|url=http://www.npr.org/blogs/health/2012/01/09/144906236/nicotine-patches-up-early-memory-loss-in-study|accessdate=3 February 2014|date=9 January 2013}}</ref> Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with [[ADHD]].<ref>{{cite web|last=Cocores,|first=James A.|title=Transdermal Nicotine in Adult ADHD With Depression and Anxiety|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446482/|publisher=National Center for Biotechnology Information, U.S. National Library of Medicine|accessdate=25 November 2013|year=2008}}</ref> {{vs|date=August 2013}} Transdermal nicotine patches can be used to relieve [[ulcerative colitis]] symptoms. However, this is not the case with [[Crohn's disease]], a similar health condition, where smoking and nicotine intake in general worsen the disease's effects. ==See also== * [[Murray Jarvik]] * [[Smoking cessation]] * [[Nicotine replacement therapy]] * [[Nicotine lozenge]] * [[Nicotine gum]] * [[Transdermal patch]] * [[Nicoderm CQ]] ==References== <references /> {{Dosage forms|state=show}} {{Routes of administration}} {{DEFAULTSORT:Nicotine Patch}} [[Category:Smoking cessation]] [[Category:Transdermal patches]]'
New page wikitext, after the edit (new_wikitext)
''
Unified diff of changes made by edit (edit_diff)
'@@ -1,37 +1 @@ -{{Cleanup|date=July 2009}} -[[Image:Nicoderm.JPG||thumb|right|A 21 mg dose [[Nicoderm]] CQ patch applied to the left arm]] -A '''nicotine patch''' is a [[transdermal patch]] that releases [[nicotine]] into the body through the skin. It is used as an aid in [[nicotine replacement therapy]] (NRT), a process for [[smoking cessation]]. The first study of the pharmacokinetics of a transdermal nicotine patch in humans was published in 1984<ref>{{cite pmid | 6734425 }}</ref> by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, and was followed by publication by Rose et al. (1985) of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes.<ref>{{cite pmid | 4042528 }}</ref> Frank Etscorn filed a patent in the [[United States]] on January the 23rd 1985 and was issued the patent on July 1, 1986.<ref>{{ cite patent | country = US | number = 4597961 | status = | title = | pubdate = | gdate = | fdate = | pridate = | inventor =Etscorn, FT | invent1 = | invent2 = | assign1 = | assign2 = | class = }}</ref> The University of California filed a competing patent application nearly 3 years after Etscorn's filing on February the 19th, 1988, which was granted on May 1, 1990.<ref>{{cite patent | country = US | number = 4920989 }}</ref> Subsequently, the U.S. Patent Office declared an interference action and, after a thorough review of conception, reduction to practice and patent filing dates, issued on September 29, 1993 a priority decision in favor of the Rose et al. patent.<ref>{{cite web|title=Adverse Decisions in Interference|url=http://www.uspto.gov/web/offices/com/sol/og/1995/week08/patadve.htm|accessdate=25 November 2013|date=21 February 1995|publisher= Board of Patent Appeals & Interferences|author=OLIVIA M. DUVALL}}</ref> Eventually New Mexico Tech and Etscorn won discovery. -==Issues== - -===Efficacy=== -Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment. Placebo tests show a 5.9% success rate, in comparison to the 7.2% blind active tests, and the 10.8% open tests.<ref>{{cite web|last=Renshaw|first=Amy|title=The Real Story Behind the Nicotine Patch and Smoking Cessation|url=http://healthpsych.psy.vanderbilt.edu/health-patch.htm|work=vanderbilt.edu|publisher=Vanderbilt University|accessdate=25 November 2013}}</ref><ref>Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009</ref> - -===Toxicity=== -Analysis of nicotine patches has shown that they contain [[tobacco-specific nitrosamines]] (TSNAs), known cancer-causing agents, in quantities of up to 173&nbsp;ng per patch.<ref>UCSF Library, 3 Feb 1995, [http://www.legacy.library.ucsf.edu/documentStore/n/y/a/nya24e00/Snya24e00.pdf Tobacco-Specific N-Nitrosamines in Nicotine Patches], retrieved 11 Aug 2013.</ref> - -==Alternate uses== -Nicotine patches are under study to help relieve the symptoms of [[post-surgical pain]] <ref>{{cite web|title=Nicotine Patch Decreases Post Surgical Pain|url=http://www.medicalnewstoday.com/releases/85508.php|publisher=MediLexicon International Ltd, Bexhill-on-Sea, UK|accessdate=25 November 2013|date=15 October 2007}}</ref> and treat early [[dementia]]. <ref>{{cite web|title=Nicotine Patches Up Early Memory Loss In Study|url=http://www.npr.org/blogs/health/2012/01/09/144906236/nicotine-patches-up-early-memory-loss-in-study|accessdate=3 February 2014|date=9 January 2013}}</ref> - -Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with [[ADHD]].<ref>{{cite web|last=Cocores,|first=James A.|title=Transdermal Nicotine in Adult ADHD With Depression and Anxiety|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446482/|publisher=National Center for Biotechnology Information, U.S. National Library of Medicine|accessdate=25 November 2013|year=2008}}</ref> {{vs|date=August 2013}} - -Transdermal nicotine patches can be used to relieve [[ulcerative colitis]] symptoms. However, this is not the case with [[Crohn's disease]], a similar health condition, where smoking and nicotine intake in general worsen the disease's effects. - -==See also== -* [[Murray Jarvik]] -* [[Smoking cessation]] -* [[Nicotine replacement therapy]] -* [[Nicotine lozenge]] -* [[Nicotine gum]] -* [[Transdermal patch]] -* [[Nicoderm CQ]] - -==References== -<references /> - -{{Dosage forms|state=show}} -{{Routes of administration}} - -{{DEFAULTSORT:Nicotine Patch}} -[[Category:Smoking cessation]] -[[Category:Transdermal patches]] '
New page size (new_size)
0
Old page size (old_size)
4682
Size change in edit (edit_delta)
-4682
Lines added in edit (added_lines)
[]
Lines removed in edit (removed_lines)
[ 0 => '{{Cleanup|date=July 2009}}', 1 => '[[Image:Nicoderm.JPG||thumb|right|A 21 mg dose [[Nicoderm]] CQ patch applied to the left arm]]', 2 => 'A '''nicotine patch''' is a [[transdermal patch]] that releases [[nicotine]] into the body through the skin. It is used as an aid in [[nicotine replacement therapy]] (NRT), a process for [[smoking cessation]]. The first study of the pharmacokinetics of a transdermal nicotine patch in humans was published in 1984<ref>{{cite pmid | 6734425 }}</ref> by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, and was followed by publication by Rose et al. (1985) of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes.<ref>{{cite pmid | 4042528 }}</ref> Frank Etscorn filed a patent in the [[United States]] on January the 23rd 1985 and was issued the patent on July 1, 1986.<ref>{{ cite patent | country = US | number = 4597961 | status = | title = | pubdate = | gdate = | fdate = | pridate = | inventor =Etscorn, FT | invent1 = | invent2 = | assign1 = | assign2 = | class = }}</ref> The University of California filed a competing patent application nearly 3 years after Etscorn's filing on February the 19th, 1988, which was granted on May 1, 1990.<ref>{{cite patent | country = US | number = 4920989 }}</ref> Subsequently, the U.S. Patent Office declared an interference action and, after a thorough review of conception, reduction to practice and patent filing dates, issued on September 29, 1993 a priority decision in favor of the Rose et al. patent.<ref>{{cite web|title=Adverse Decisions in Interference|url=http://www.uspto.gov/web/offices/com/sol/og/1995/week08/patadve.htm|accessdate=25 November 2013|date=21 February 1995|publisher= Board of Patent Appeals & Interferences|author=OLIVIA M. DUVALL}}</ref> Eventually New Mexico Tech and Etscorn won discovery.', 3 => '==Issues==', 4 => false, 5 => '===Efficacy===', 6 => 'Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment. Placebo tests show a 5.9% success rate, in comparison to the 7.2% blind active tests, and the 10.8% open tests.<ref>{{cite web|last=Renshaw|first=Amy|title=The Real Story Behind the Nicotine Patch and Smoking Cessation|url=http://healthpsych.psy.vanderbilt.edu/health-patch.htm|work=vanderbilt.edu|publisher=Vanderbilt University|accessdate=25 November 2013}}</ref><ref>Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009</ref>', 7 => false, 8 => '===Toxicity===', 9 => 'Analysis of nicotine patches has shown that they contain [[tobacco-specific nitrosamines]] (TSNAs), known cancer-causing agents, in quantities of up to 173&nbsp;ng per patch.<ref>UCSF Library, 3 Feb 1995, [http://www.legacy.library.ucsf.edu/documentStore/n/y/a/nya24e00/Snya24e00.pdf Tobacco-Specific N-Nitrosamines in Nicotine Patches], retrieved 11 Aug 2013.</ref>', 10 => false, 11 => '==Alternate uses==', 12 => 'Nicotine patches are under study to help relieve the symptoms of [[post-surgical pain]] <ref>{{cite web|title=Nicotine Patch Decreases Post Surgical Pain|url=http://www.medicalnewstoday.com/releases/85508.php|publisher=MediLexicon International Ltd, Bexhill-on-Sea, UK|accessdate=25 November 2013|date=15 October 2007}}</ref> and treat early [[dementia]]. <ref>{{cite web|title=Nicotine Patches Up Early Memory Loss In Study|url=http://www.npr.org/blogs/health/2012/01/09/144906236/nicotine-patches-up-early-memory-loss-in-study|accessdate=3 February 2014|date=9 January 2013}}</ref>', 13 => false, 14 => 'Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with [[ADHD]].<ref>{{cite web|last=Cocores,|first=James A.|title=Transdermal Nicotine in Adult ADHD With Depression and Anxiety|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446482/|publisher=National Center for Biotechnology Information, U.S. National Library of Medicine|accessdate=25 November 2013|year=2008}}</ref> {{vs|date=August 2013}}', 15 => false, 16 => 'Transdermal nicotine patches can be used to relieve [[ulcerative colitis]] symptoms. However, this is not the case with [[Crohn's disease]], a similar health condition, where smoking and nicotine intake in general worsen the disease's effects.', 17 => false, 18 => '==See also==', 19 => '* [[Murray Jarvik]]', 20 => '* [[Smoking cessation]]', 21 => '* [[Nicotine replacement therapy]]', 22 => '* [[Nicotine lozenge]]', 23 => '* [[Nicotine gum]]', 24 => '* [[Transdermal patch]]', 25 => '* [[Nicoderm CQ]]', 26 => false, 27 => '==References==', 28 => '<references />', 29 => false, 30 => '{{Dosage forms|state=show}}', 31 => '{{Routes of administration}}', 32 => false, 33 => '{{DEFAULTSORT:Nicotine Patch}}', 34 => '[[Category:Smoking cessation]]', 35 => '[[Category:Transdermal patches]]' ]
Whether or not the change was made through a Tor exit node (tor_exit_node)
0
Unix timestamp of change (timestamp)
1410340300